| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00430-008-0093-2 |
| P8608 | Fatcat ID | release_hjiqhb5auvdrndli3a4bcfwx5y |
| P698 | PubMed publication ID | 18343947 |
| P5875 | ResearchGate publication ID | 5508299 |
| P50 | author | Matthias J Reddehase | Q62925338 |
| Rafaela Holtappels | Q92198001 | ||
| P2093 | author name string | Jürgen Podlech | |
| Verena Böhm | |||
| P2860 | cites work | The murine cytomegalovirus immunomodulatory gene m152 prevents recognition of infected cells by M45-specific CTL but does not alter the immunodominance of the M45-specific CD8 T cell response in vivo | Q31084489 |
| Genome-wide analysis reveals a highly diverse CD8 T cell response to murine cytomegalovirus | Q33235520 | ||
| Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting | Q33755031 | ||
| Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence | Q33782273 | ||
| Control of murine cytomegalovirus in the lungs: relative but not absolute immunodominance of the immediate-early 1 nonapeptide during the antiviral cytolytic T-lymphocyte response in pulmonary infiltrates | Q33783800 | ||
| Control of cytomegalovirus in bone marrow transplantation chimeras lacking the prevailing antigen-presenting molecule in recipient tissues rests primarily on recipient-derived CD8 T cells | Q33784524 | ||
| The putative natural killer decoy early gene m04 (gp34) of murine cytomegalovirus encodes an antigenic peptide recognized by protective antiviral CD8 T cells | Q33797749 | ||
| Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65) | Q33802461 | ||
| Murine model of interstitial cytomegalovirus pneumonia in syngeneic bone marrow transplantation: persistence of protective pulmonary CD8-T-cell infiltrates after clearance of acute infection | Q33809769 | ||
| Enrichment of immediate-early 1 (m123/pp89) peptide-specific CD8 T cells in a pulmonary CD62L(lo) memory-effector cell pool during latent murine cytomegalovirus infection of the lungs | Q33812288 | ||
| OX40 costimulation promotes persistence of cytomegalovirus-specific CD8 T Cells: A CD4-dependent mechanism. | Q43644014 | ||
| Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantation recipients by adoptive transfer of donor-derived CMV-specific T cell clones expanded in vitro | Q44551855 | ||
| Immunotherapy of cytomegalovirus infection after stem-cell transplantation: a new option? | Q44636718 | ||
| Significance of herpesvirus immediate early gene expression in cellular immunity to cytomegalovirus infection | Q59057908 | ||
| Coordinated Function of Murine Cytomegalovirus Genes Completely Inhibits CTL Lysis | Q60214617 | ||
| Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones | Q67518698 | ||
| Lack of MHC class I complex expression has no effect on spread and control of cytomegalovirus infection in vivo | Q71071690 | ||
| Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor | Q72059554 | ||
| Reconstitution of CD8 T cells is essential for the prevention of multiple-organ cytomegalovirus histopathology after bone marrow transplantation | Q77331536 | ||
| Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance | Q78471193 | ||
| Adoptive CD8 T cell control of pathogens cannot be improved by combining protective epitope specificities | Q80609133 | ||
| Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for ppM83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65). | Q33843590 | ||
| Role of specific cytotoxic lymphocytes in cellular immunity against murine cytomegalovirus | Q33900303 | ||
| Frequent coinfection of cells explains functional in vivo complementation between cytomegalovirus variants in the multiply infected host | Q33908684 | ||
| Haematopoietic cell transplantation as immunotherapy | Q34253590 | ||
| Principles for adoptive T cell therapy of human viral diseases | Q34300059 | ||
| Two antigenic peptides from genes m123 and m164 of murine cytomegalovirus quantitatively dominate CD8 T-cell memory in the H-2d haplotype | Q34327234 | ||
| Development of a vaccine against murine cytomegalovirus (MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, that provides long-term, complete protection against viral replication | Q34338715 | ||
| Role of T lymphocytes in recovery from murine cytomegalovirus infection | Q34413619 | ||
| Lymphoma cell apoptosis in the liver induced by distant murine cytomegalovirus infection | Q34647659 | ||
| Strong CD8 T-cell responses following coimmunization with plasmids expressing the dominant pp89 and subdominant M84 antigens of murine cytomegalovirus correlate with long-term protection against subsequent viral challenge | Q34970937 | ||
| Cytomegalovirus encodes a positive regulator of antigen presentation | Q35023830 | ||
| CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation | Q35139332 | ||
| Clinical aspects of CMV infection after stem cell transplantation | Q35789339 | ||
| DNA immunization confers protection against murine cytomegalovirus infection | Q35872388 | ||
| DNA immunization using highly conserved murine cytomegalovirus genes encoding homologs of human cytomegalovirus UL54 (DNA polymerase) and UL105 (helicase) elicits strong CD8 T-cell responses and is protective against systemic challenge. | Q35914513 | ||
| Cellular immunotherapy for viral infection after HSC transplantation | Q35998792 | ||
| In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection | Q36352435 | ||
| Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects | Q36402863 | ||
| Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers | Q36403280 | ||
| Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells | Q36403419 | ||
| Dominant-negative FADD rescues the in vivo fitness of a cytomegalovirus lacking an antiapoptotic viral gene | Q36483846 | ||
| Restoration of cytomegalovirus antigen presentation by gamma interferon combats viral escape. | Q36619640 | ||
| Efficacious control of cytomegalovirus infection after long-term depletion of CD8+ T lymphocytes | Q36793382 | ||
| Cloned long-term cytolytic T-lymphocyte line with specificity for an immediate-early membrane antigen of murine cytomegalovirus | Q36857050 | ||
| Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs | Q36903040 | ||
| CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity | Q36919192 | ||
| Murine model of cytomegalovirus latency and reactivation. | Q37220009 | ||
| Multiple epitopes in the murine cytomegalovirus early gene product M84 are efficiently presented in infected primary macrophages and contribute to strong CD8+-T-lymphocyte responses and protection following DNA immunization | Q37567900 | ||
| Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. | Q39595809 | ||
| Role of murine cytomegalovirus US22 gene family members in replication in macrophages | Q39748997 | ||
| Adoptive immunotherapy of murine cytomegalovirus adrenalitis in the immunocompromised host: CD4-helper-independent antiviral function of CD8-positive memory T lymphocytes derived from latently infected donors. | Q40130010 | ||
| Viral interference with antigen presentation does not alter acute or chronic CD8 T cell immunodominance in murine cytomegalovirus infection | Q40130284 | ||
| Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T cell responses in children with congenital or postnatal human cytomegalovirus infection | Q40592122 | ||
| Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. | Q40621588 | ||
| Pathogenesis of cytomegalovirus pneumonia in immunocompromised hosts. | Q41007762 | ||
| Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses | Q42120952 | ||
| Cytomegalovirus misleads its host by priming of CD8 T cells specific for an epitope not presented in infected tissues | Q42753262 | ||
| P433 | issue | 2 | |
| P921 | main subject | Cytomegalovirus | Q6946 |
| immunotherapy | Q1427096 | ||
| cytomegaloviral disease | Q2076966 | ||
| murine model | Q122890741 | ||
| P304 | page(s) | 125-134 | |
| P577 | publication date | 2008-03-15 | |
| P1433 | published in | Medical Microbiology and Immunology | Q15760239 |
| P1476 | title | CD8 T-cell-based immunotherapy of cytomegalovirus infection: "proof of concept" provided by the murine model | |
| P478 | volume | 197 |
| Q42278604 | Adoptive transfer of cytomegalovirus-specific effector CD4+ T cells provides antiviral protection from murine CMV infection |
| Q84952536 | Antigen presentation under the influence of 'immune evasion' proteins and its modulation by interferon-gamma: implications for immunotherapy of cytomegalovirus infection with antiviral CD8 T cells |
| Q36397454 | Antiviral T cell response triggers cytomegalovirus hepatitis in mice |
| Q64450813 | CD8 T-Cell Immunotherapy of Cytomegalovirus Disease in the Murine Model |
| Q64123448 | Coincident airway exposure to low-potency allergen and cytomegalovirus sensitizes for allergic airway disease by viral activation of migratory dendritic cells |
| Q33813837 | Comparison of multiple DNA vaccines for protection against cytomegalovirus infection in BALB/c mice |
| Q57278728 | Control of primary mouse cytomegalovirus infection in lung nodular inflammatory foci by cooperation of interferon-gamma expressing CD4 and CD8 T cells |
| Q38703382 | Cytomegalovirus and immunotherapy: opportunistic pathogen, novel target for cancer and a promising vaccine vector. |
| Q37559627 | Cytomegalovirus and varicella-zoster virus vaccines in hematopoietic stem cell transplantation |
| Q94564147 | Cytomegalovirus-Associated Inhibition of Hematopoiesis Is Preventable by Cytoimmunotherapy With Antiviral CD8 T Cells |
| Q47556818 | Editorship for Medical Microbiology and Immunology: the baton has been passed on. |
| Q37651700 | Enforced OX40 Stimulation Empowers Booster Vaccines to Induce Effective CD4+ and CD8+ T Cell Responses against Mouse Cytomegalovirus Infection |
| Q35693349 | Evaluating Human T-Cell Therapy of Cytomegalovirus Organ Disease in HLA-Transgenic Mice |
| Q55002157 | HCMV triggers frequent and persistent UL40-specific unconventional HLA-E-restricted CD8 T-cell responses with potential autologous and allogeneic peptide recognition. |
| Q35585875 | Identification of an atypical CD8 T cell epitope encoded by murine cytomegalovirus ORF-M54 gaining dominance after deletion of the immunodominant antiviral CD8 T cell specificities. |
| Q84971601 | Immune control in the absence of immunodominant epitopes: implications for immunotherapy of cytomegalovirus infection with antiviral CD8 T cells |
| Q37356040 | Immune evasion proteins enhance cytomegalovirus latency in the lungs. |
| Q33614398 | Immune evasion proteins of murine cytomegalovirus preferentially affect cell surface display of recently generated peptide presentation complexes |
| Q37773240 | Immune-based therapies for cytomegalovirus infection |
| Q37798997 | In vivo impact of cytomegalovirus evasion of CD8 T-cell immunity: facts and thoughts based on murine models. |
| Q34556966 | Is human cell therapy research caught in a mousetrap? |
| Q38342824 | Mast cells: innate attractors recruiting protective CD8 T cells to sites of cytomegalovirus infection. |
| Q58801058 | Maternal Immunity and the Natural History of Congenital Human Cytomegalovirus Infection |
| Q36384572 | Memory T cells specific for murine cytomegalovirus re-emerge after multiple challenges and recapitulate immunity in various adoptive transfer scenarios. |
| Q60913862 | Mouse Model of Cytomegalovirus Disease and Immunotherapy in the Immunocompromised Host: Predictions for Medical Translation that Survived the "Test of Time" |
| Q38041963 | Murine cytomegalovirus immune evasion proteins operative in the MHC class I pathway of antigen processing and presentation: state of knowledge, revisions, and questions |
| Q26740328 | Mutual Interference between Cytomegalovirus and Reconstitution of Protective Immunity after Hematopoietic Cell Transplantation |
| Q37611838 | Noncanonical expression of a murine cytomegalovirus early protein CD8 T-cell epitope as an immediate early epitope based on transcription from an upstream gene. |
| Q44245356 | Nucleocytoplasmic shuttling and CRM1-dependent MHC class I peptide presentation of human cytomegalovirus pp65. |
| Q37387045 | Oncomodulation by human cytomegalovirus: evidence becomes stronger. |
| Q34145201 | Oncomodulation by human cytomegalovirus: novel clinical findings open new roads |
| Q38042835 | Parameters determining the efficacy of adoptive CD8 T-cell therapy of cytomegalovirus infection. |
| Q38381730 | Principles for studying in vivo attenuation of virus mutants: defining the role of the cytomegalovirus gH/gL/gO complex as a paradigm. |
| Q34360228 | Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties. |
| Q36999665 | Reconstitution of CD8 T Cells Protective against Cytomegalovirus in a Mouse Model of Hematopoietic Cell Transplantation: Dynamics and Inessentiality of Epitope Immunodominance. |
| Q38931391 | Refining human T-cell immunotherapy of cytomegalovirus disease: a mouse model with 'humanized' antigen presentation as a new preclinical study tool |
| Q34495529 | Reverse genetics modification of cytomegalovirus antigenicity and immunogenicity by CD8 T-cell epitope deletion and insertion |
| Q35382729 | Reversible inhibition of murine cytomegalovirus replication by gamma interferon (IFN-γ) in primary macrophages involves a primed type I IFN-signaling subnetwork for full establishment of an immediate-early antiviral state |
| Q36673260 | Subdominant CD8 T-cell epitopes account for protection against cytomegalovirus independent of immunodomination |
| Q33806000 | Suppression of adaptive immune responses during primary SIV infection of sabaeus African green monkeys delays partial containment of viremia but does not induce disease. |
| Q33845720 | Systemic hematogenous maintenance of memory inflation by MCMV infection. |
| Q38815977 | T cell responses to cytomegalovirus |
| Q40211958 | TLR3-independent activation of mast cells by cytomegalovirus contributes to control of pulmonary infection. |
| Q41887918 | The efficacy of antigen processing is critical for protection against cytomegalovirus disease in the presence of viral immune evasion proteins. |
| Q36974716 | The immune evasion paradox: immunoevasins of murine cytomegalovirus enhance priming of CD8 T cells by preventing negative feedback regulation. |
| Q36934001 | Transactivation of cellular genes involved in nucleotide metabolism by the regulatory IE1 protein of murine cytomegalovirus is not critical for viral replicative fitness in quiescent cells and host tissues |
| Q37632938 | γδ T Cell-Mediated Immunity to Cytomegalovirus Infection. |
Search more.